Chen Wei, Antonenko Svetlana, Sederstrom Joel M, Liang Xueqing, Chan Anissa S H, Kanzler Holger, Blom Bianca, Blazar Bruce R, Liu Yong-Jun
Cancer Center and Department of Pediatrics, Division of Hematology, Oncology, and Bone Marrow Transplantation, niversity of Minnesota, Minneapolis, MN 55455, USA.
Blood. 2004 Apr 1;103(7):2547-53. doi: 10.1182/blood-2003-09-3058. Epub 2003 Dec 11.
Type 1 interferon-producing cells (IPCs), also known as plasmacytoid dendritic cell (DC) precursors, represent the key effectors in antiviral innate immunity and triggers for adaptive immune responses. IPCs play important roles in the pathogenesis of systemic lupus erythematosus (SLE) and in modulating immune responses after hematopoietic stem cell transplantation. Understanding IPC development from hematopoietic progenitor cells (HPCs) may provide critical information in controlling viral infection, autoimmune SLE, and graft-versus-host disease. FLT3-ligand (FLT3-L) represents a key IPC differentiation factor from HPCs. Although hematopoietic cytokines such as interleukin-3 (IL-3), IL-7, stem cell factor (SCF), macrophage-colony-stimulating factor (M-CSF), and granulocyte M-CSF (GM-CSF) promote the expansion of CD34+ HPCs in FLT3-L culture, they strongly inhibit HPC differentiation into IPCs. Here we show that thrombopoietin (TPO) cooperates with FLT3-L, inducing CD34+ HPCs to undergo a 400-fold expansion in cell numbers and to generate more than 6 x 10(6) IPCs per 10(6) CD34+ HPCs within 30 days in culture. IPCs derived from HPCs in FLT3-L/TPO cultures display blood IPC phenotype and have the capacity to produce large amounts of interferon-alpha (IFN-alpha) and to differentiate into mature DCs. This culture system, combined with the use of adult peripheral blood CD34+ HPCs purified from G-CSF-mobilized donors, permits the generation of more than 10(9) IPCs from a single blood donor.
1型干扰素产生细胞(IPCs),也被称为浆细胞样树突状细胞(DC)前体,是抗病毒先天免疫中的关键效应细胞以及适应性免疫反应的触发因素。IPCs在系统性红斑狼疮(SLE)的发病机制以及造血干细胞移植后调节免疫反应中发挥重要作用。了解造血祖细胞(HPCs)向IPCs的发育过程可能为控制病毒感染、自身免疫性SLE和移植物抗宿主病提供关键信息。FMS样酪氨酸激酶3配体(FLT3-L)是HPCs向IPCs分化的关键因子。尽管造血细胞因子如白细胞介素-3(IL-3)、IL-7、干细胞因子(SCF)、巨噬细胞集落刺激因子(M-CSF)和粒细胞M-CSF(GM-CSF)可促进FLT3-L培养体系中CD34+HPCs的扩增,但它们会强烈抑制HPCs向IPCs的分化。在此我们表明,血小板生成素(TPO)与FLT3-L协同作用,可诱导CD34+HPCs在培养30天内细胞数量扩增400倍,并每10^6个CD34+HPCs产生超过6×10^6个IPCs。在FLT3-L/TPO培养体系中由HPCs衍生的IPCs表现出血液IPCs表型,具有产生大量干扰素-α(IFN-α)以及分化为成熟DCs的能力。该培养体系与从粒细胞集落刺激因子(G-CSF)动员的供体中纯化的成人外周血CD34+HPCs相结合,可从单个献血者中产生超过10^9个IPCs。